LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance.
This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...
Survival analysis anticipates the expected lifespans of individuals as well as the timing of other events. Learn about its pros and cons.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results